Pfizer (NYSE: PFE) reported Q4 EPS of $0.10, $0.28 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $14.25 billion versus the consensus estimate of $14.22 billion.

The company reaffirms Full-Year 2024 guidance provided on December 13, 2023, of Revenues of $58.5 to $61.5 Billion and Adjusted Diluted EPS of $2.05 to $2.25

For earnings history and earnings-related data on Pfizer (PFE) click here.